Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.83: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 6.67; Below-average business quality.
Agios is a commercial-stage biopharmaceutical company with two approved hematology products: PYRUKYND® (FDA/EU/Saudi Arabia) for PK deficiency and thalassemia, and AQVESME™ (FDA) for thalassemia launched in late January 2026. Revenue comes from net product sales ($54.0M... Read more
Sell if holding. Engine safety override at $27.83: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 6.67; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Score 5.0/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 89d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPYRUKYND®10-K Item 1A: 'We generated $54.0 million, $36.5 million and $26.8 million of net product revenues from sales of PYRUKYND® in the years ended December 31, 2025, 2024 and 2023, respectively.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.83: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 6.67; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 35, MACD bearish. Prior stop was $25.89. Score 5.0/10, moderate confidence.
Take-profit target: $35.78 (+28.5% upside). Prior stop was $25.89. Stop-loss: $25.89.
Concentration risk — Product: PYRUKYND®; Quality below floor (1.7 < 4.0).
Agios Pharmaceuticals, Inc. trades at a P/E of N/A (forward -6.0). TrendMatrix value score: 5.4/10. Verdict: Sell.
16 analysts cover AGIO with a consensus score of 4.1/5. Average price target: $41.
What does Agios Pharmaceuticals, Inc. do?Agios is a commercial-stage biopharmaceutical company with two approved hematology products: PYRUKYND® (FDA/EU/Saudi...
Agios is a commercial-stage biopharmaceutical company with two approved hematology products: PYRUKYND® (FDA/EU/Saudi Arabia) for PK deficiency and thalassemia, and AQVESME™ (FDA) for thalassemia launched in late January 2026. Revenue comes from net product sales ($54.0M PYRUKYND® in 2025) with a pipeline including tebapivat (LR MDS/SCD) and AG-236 (polycythemia vera).